By inmedia
Today’s CIO Insider newsletter points to a recent report by Forrester Research that analyzes the current state of IT and improvements that can be made. According to the article, “unnecessary IT complexity adds costs, reduces effectiveness and stalls innovation… the answer lies in strategic and ongoing consolidation.” But won’t this suggested consolidation cost a considerable amount? Yes indeed, between 10 and 25 percent of the IT budget or more in some cases. IT managers and CIOs can mitigate this expenditure by planning “consolidation as a strategic initiative; use functions that can be resourced, monitored, measured and charged for as a framework to guide consolidation; and manage consolidation as an IT transformation program.” For more tips on maximizing IT potential, read the full article.
By inmedia
Today’s Popgadget newsletter pointed me to a great list, 101 gadgets that changed the world. The list includes many gadgets we’ve come to rely on and others we’ve long since taken for granted. Head on over to the Belfast Telegraph to check it out.
By inmedia
As part of NBC’s Green Week, the Sci Fi Tech blog has published an entry about the top eight fuels of the future. The post highlights up-and-coming fuel sources, including hydrogen, biofuels, solar, wind, batteries, tides, garbage and nuclear fusion. For all the details, click here.
By inmedia
Looks like online retailers still have a long way to go. Today’s Customer Management newsletter reveals the results of a new survey that indicates almost 9 out of 10 British online consumers have experienced “problems completing transactions.” Apparently 37% of those surveyed also said they would “abandon their transaction entirely if they experienced a problem.” Seems like a lot of potential revenue is being lost there.
More interesting findings from the survey are revealed in the full article.
By inmedia
There has been a trend emerging in recent years of pharmaceutical companies creating generic versions of successful off-patent drugs as a method of speeding the laborious, expensive and time consuming clinical and regulatory requirements of bringing a drug to market. When generic drugs hit the market, typically between seven and 12 years after the brand name drug was made generally available and the 20-year patent protection has ended, the cost for both the generic and the brand name drug decrease because of the increased competition. However, the results of a study by Canada’s Competition Bureau show that Canadians could be paying less for these drugs than they currently are. The rebates that generic providers are giving to pharmacies as incentive to stock their products are not being passed along to the consumer. The full study, which explains why these benefits are not reaching the consumer and suggests possible solutions, is available on the Competition Bureau’s web site.
